<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453570</url>
  </required_header>
  <id_info>
    <org_study_id>E2I42</org_study_id>
    <nct_id>NCT00453570</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As per request by the Heath Authorities, the present clinical study will assess the&#xD;
      immunogenicity and safety of sanofi pasteur's DTacP-IPV// PRP~T combined vaccine (PENTAXIM™)&#xD;
      as a three-dose primary vaccination at 2, 3, and 4 months of age or 3, 4 and 5 months of age&#xD;
      followed by a booster dose at 18-20 months of age as compared to commercially available&#xD;
      DTacP, Hib conjugate (Act-HIB™) and IPV (IMOVAX Polio™) monovalent vaccines in order to meet&#xD;
      the requirements for registration of the product in People's Republic of China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the immunogenicity of DTacP-IPV//PRP~T combined vaccine</measure>
    <time_frame>1 Month post-dose 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To provide information concerning the safety of DTacP-IPV//PRP~T combined vaccine</measure>
    <time_frame>19 months post-dose 1</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">792</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Haemophilus Influenzae Type b</condition>
  <condition>Pertussis</condition>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTacP IPV// PRP~T combined vaccine at 2, 3 and 4 months of age, and a booster dose at 18-20 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTacP-IPV// PRP~T combined vaccine at 3, 4 and 5 months of age and a booster dose at 18-20 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control vaccines at 3, 4 and 5 months of age and a booster dose at 18-20 months of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>1</arm_group_label>
    <other_name>PENTAXIM™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>2</arm_group_label>
    <other_name>PENTAXIM™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diphtheria, Tetanus, &amp; Acellular Pertussis Combined, Absorbed</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>3</arm_group_label>
    <other_name>DTacP, Act-HIB™ and IMOVAX Polio™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  Aged 2 months (60 to 74 days) inclusive on the day of inclusion&#xD;
&#xD;
          -  Born at full term pregnancy (³36 weeks) with a birth weight ≥ 2.5 kg&#xD;
&#xD;
          -  Informed consent form signed by the parent(s) or other legal representative&#xD;
&#xD;
          -  Able to attend all scheduled visits and to comply with all trial procedures&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          -  Participation in another clinical trial in the 4 weeks preceding the trial inclusion&#xD;
&#xD;
          -  Planned participation in another clinical trial during the present trial period&#xD;
&#xD;
          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term&#xD;
             systemic corticosteroids therapy&#xD;
&#xD;
          -  Systemic hypersensitivity to any of the vaccine components or history of a life&#xD;
             threatening reaction to the trial vaccine or a vaccine containing the same substances&#xD;
&#xD;
          -  Chronic illness at a stage that could interfere with trial conduct or completion&#xD;
&#xD;
          -  Blood or blood-derived products received in the past&#xD;
&#xD;
          -  Any vaccination performed or planned in the 4 weeks preceding the first trial visit&#xD;
             (except BCG and Hepatitis B, which can not be given within 8 days before the first&#xD;
             study visit)&#xD;
&#xD;
          -  Vaccination planned in the 4 weeks following any trial vaccination (except BCG and&#xD;
             Hepatitis B, which can not be given within 8 days before or after the study vaccine(s)&#xD;
             administration)&#xD;
&#xD;
          -  History of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type&#xD;
             b infection (confirmed either clinically, serologically or microbiologically)&#xD;
&#xD;
          -  Clinical or serological evidence of systemic illness including Hepatitis B, Hepatitis&#xD;
             C and/or HIV infection&#xD;
&#xD;
          -  Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis&#xD;
             diseases or Haemophilus influenzae type b infection with the trial vaccine or another&#xD;
             vaccine&#xD;
&#xD;
          -  Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination&#xD;
&#xD;
          -  History of/current seizures&#xD;
&#xD;
          -  Febrile illness (axillary temperature ≥ 37.1°C) or acute illness on the day of&#xD;
             inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Days</minimum_age>
    <maximum_age>74 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>March 28, 2007</study_first_submitted>
  <study_first_submitted_qc>March 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2007</study_first_posted>
  <last_update_submitted>April 13, 2012</last_update_submitted>
  <last_update_submitted_qc>April 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphteria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Haemophilus influenzae type b</keyword>
  <keyword>Poliomyelitis</keyword>
  <keyword>Pertussis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

